Stopping rivastigmine patch should be a prescriber-supervised, monitored decision rather than an irreversible choice made at home. Ask whether the medicine still has a valid purpose, whether benefits outweigh harms, and how it should be tapered and monitored. The rivastigmine patch delivers a medicine used to manage dementia symptoms; it does not cure or stop the underlying disease. Some people benefit while others do not, and decline over time does not by itself prove that the patch has stopped helping.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does the patch still have a clear purpose?
- Is advanced dementia enough reason to stop?
- Are side effects changing the balance?
- How should a stopping trial work?
- What if treatment has already been interrupted?
Does the patch still have a clear purpose?
Ask the prescriber to confirm the diagnosis and treatment goal. DailyMed lists the patch for mild-to-severe Alzheimer's dementia and mild-to-moderate Parkinson's disease dementia, with continued treatment at an effective maintenance dose only while benefit persists for the specified stages and conditions in the current U.S.
prescribing information. "Benefit" may be difficult to see because the medicine is symptomatic, not curative. Useful questions include:.
- What improvement or stabilization was noticed after treatment began?
- Which abilities might the patch still be supporting?
- Has cognition or daily function declined substantially despite treatment?
- Was a meaningful benefit ever documented?
- What would count as evidence that stopping was a mistake?
Is advanced dementia enough reason to stop?
Not necessarily. NICE says Alzheimer's disease severity alone is not a sufficient reason to stop an acetylcholinesterase inhibitor, the medicine class that includes rivastigmine in its dementia guideline. NICE also recommends considering or offering added memantine in established moderate or severe Alzheimer's disease.
A separate deprescribing guideline supports considering monitored discontinuation after more than 12 months when cognition or function has significantly worsened, no benefit was ever seen, or dementia is severe or end-stage. However, the guideline rates the certainty of this evidence as low. The decision therefore needs more than a stage label: it should reflect treatment goals, observed benefit, current function, and medication burden.
Are side effects changing the balance?
Ask whether nausea, vomiting, diarrhea, appetite loss, weight loss, or dehydration could be related to rivastigmine. These effects can be dose-related, and prolonged vomiting or diarrhea may lead to serious outcomes, according to DailyMed's safety information.
A skin reaction also deserves careful assessment. The label directs discontinuation for suspected allergic contact dermatitis when redness or swelling spreads beyond the patch, becomes more intense, or does not substantially improve within 48 hours after removal. Oral rivastigmine should then be considered only after negative allergy testing and under close supervision.
How should a stopping trial work?
Ask for written instructions rather than removing the patch and waiting without a plan. The deprescribing guideline advises halving the dose or stepping down through available strengths every four weeks, with close monitoring and restarting when withdrawal is followed by clear deterioration in its tapering recommendations. Before reducing the dose, record a practical baseline that the caregiver and prescriber can compare later: Ask who should receive updates, how often progress will be reviewed, and what specific change would trigger restarting treatment.
- Usual memory and communication
- Ability to complete familiar daily activities
- Appetite, weight, vomiting, or diarrhea
- The date and strength of each dose change
- Any clear decline after a reduction
What if treatment has already been interrupted?
Tell the prescriber exactly when the last patch was removed and what strength was being used. An interruption is not the same as a planned taper, especially if it happened because of vomiting, diarrhea, a skin reaction, or another suspected adverse effect.
If treatment has been interrupted for more than three days, the U.S. label says not to resume the former strength automatically. Treatment must restart at 4.6 mg per 24 hours and be increased again as directed, particularly after an interruption caused by intolerance, to reduce the risk of severe vomiting.
